Dual PDE-5 inhibitor, 5-ARI therapy improves LUTS
March 25th 2013Co-administration of a phosphodiesterase type-5 inhibitor and a 5-alpha-reductase inhibitor significantly improved scores on the International Prostate Symptom Score (IPSS), compared to placebo plus the 5-ARI in men with lower urinary tract symptoms of BPH and enlarged prostates, researchers reported at the European Association of Urology annual congress in Milan, Italy.
ASTRO on proton therapy: More research needed
March 18th 2013The American Society for Radiation Oncology’s board of directors recently approved a statement regarding the use of proton beam therapy for prostate cancer, presumably due to recent reports suggesting the treatment provides little long-term benefit over traditional radiation despite its higher cost.
AUGS issues guide on sacrocolpopexy credentialing
March 18th 2013The American Urogynecologic Society (AUGS) has released new guidelines for privileging and credentialing physicians for sacrocolpopexy in an effort to assist health care institutions when considering granting privileges to perform the procedure for pelvic organ prolapse (POP).
What changes to the –59 modifier mean for you
March 15th 2013We’ve received a number of questions pertaining to the change in Medicare rules regarding the –59 modifier. Although in a previous column we discussed this change in relation to kidney stones specifically, we feel the interest generated by this change warrants a deeper dive into this subject.
The OIG: What you don’t know can hurt you
March 12th 2013In a series of three articles, I examine the Office of the Inspector General, explain its relevance to urologists and their practice, and provide practical tips to understand and manage any risks associated with the activities of this institution. In this first installment, I provide an overview of the institution and review what it will be examining in 2013.
Cleveland Clinic acquires Las Vegas urology practice
March 11th 2013Cleveland Clinic’s Glickman Urological & Kidney Institute will begin offering urology services in Las Vegas in mid-April, the result of Cleveland Clinic’s acquisition of the private practice of local urologists Scott Slavis, MD, and Laurie Larsen, MD.
IPP placement post-T-shunt surgery appears efficacious
March 6th 2013Placement of an inflatable penile prosthesis (IPP) approximately 3 months after T-shunt surgery in men with acute ischemic priapism and refractory erectile dysfunction is associated with favorable outcomes at 1 year, according to data from a small series of such patients.
Novel VEGF inhibitor may play role in advanced renal cell carcinoma
March 6th 2013Use of tivozanib, an experimental tyrosine kinase inhibitor (TKI) with increased specificity and potency for the vascular endothelial growth factor (VEGF) receptor, as initial targeted therapy for patients with advanced renal cell carcinoma did not translate into improved overall survival compared with sorafenib (Nexavar) in a phase III clinical trial.